Critical coronavirus warning: Initial vaccines may be flawed
Kate Bingham, Head of the UK Vaccine Task Force, said, "Initial vaccines may be flawed and not beneficial for everyone." warned.
Bingham, in his article for the famous medical journal Lancet, stated that no vaccine in the history of medicine is expected as much as the Kovid-19 vaccine.
Noting that the only way to get rid of the epidemic is "vaccination", Bingham warned not to be overly optimistic about the first vaccines.
Bingham said, "The first vaccines to be produced will probably not be perfect. The next generation vaccines may be flawed and not beneficial for everyone. We must be prepared for this." used expressions.
UK VACCINE TASK FORCE
The UK Vaccine Task Force was founded by Sir Patrick Vallance, who is currently acting as the government's science advisor, to support potential Kovid-19 vaccine studies in collaboration with the public and private sectors, mobilize funding for studies and monitor clinical trials.
Kate Bingham, chairman of the Vaccine Task Force, presents Prime Minister Boris Johnson with reports on vaccination studies.
The second and third stages in the UK and India for the vaccine candidate "AZD1222", developed by the Oxford University Jenner Institute in England and the Oxford Vaccine Group, and the production license was purchased by the British-Swedish pharmaceutical company AstraZeneca, Brazil Stage 3 clinical trials are being conducted in South Africa and the USA.
For the vaccine candidate, which is targeted to be tested on 30 thousand healthy volunteers worldwide, the USA provided 1.2 billion dollars, while the European Union (EU) countries agreed to purchase 400 million doses of vaccine from the company if the tests were successful.
The company, which produced millions of doses of vaccine to be used in trials in cooperation with the Serum Institute of India (SII), aimed to make the vaccine candidate ready for emergency use at the end of October.